Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT03034304 2025-07-24

A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors

Phase 1 Terminated

105 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1 Terminated

33 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT04261439 2025-05-06

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Phase 1 Terminated

60 enrolled

DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma

NCT04171141 2025-01-16

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Phase 1 Terminated

79 enrolled 42 charts

Gastrointestinal

Digestive System Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT03549000 2024-12-13

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Phase 1 Terminated

127 enrolled

BreastGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03716596 2024-09-20

CISPD-2

Phase 1 Terminated

8 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03301896 2024-06-20

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1 Terminated

45 enrolled

Dermatologic

Melanoma

NCT02452268 2023-03-03

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

Phase 1 Terminated

83 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT02607813 2022-12-21

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Phase 1 Terminated

142 enrolled

DermatologicGynecologic

Melanoma, Ovarian Neoplasms

NCT03064854 2022-08-15

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Phase 1 Terminated

111 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03172936 2022-05-03

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Phase 1 Terminated

106 enrolled

Lymphoid

Lymphoma

NCT03176264 2021-10-12

PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer

Phase 1 Terminated

1 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03707457 2020-07-02

Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma

Phase 1 Terminated

3 enrolled

CNS

Glioblastoma